Sterile fill-finish capacity in the United States is tightening as demand rises, technology standards evolve and acquisitions reshape the CDMO landscape. In this sponsored episode of The Top Line, Denis Johnson, CEO of Grand River Aseptic Manufacturing, outlines why he expects increased demand, deeper specialization and greater segmentation across the sterile fill market over the next three years.
Johnson cites the shift from RABS to isolator technology, Annex 1 expectations and renewed focus on U.S.-based manufacturing as key forces driving change. At the same time, he says expertise — not just equipment — will define success. As more companies reshore production and launch complex biologics, the real bottleneck may be experienced talent capable of supporting compliant, efficient tech transfer and commercialization.
Hear how GRAM is investing in new facilities, expanding its sterile filling lines, and hiring and training teams months in advance to help ensure quality and speed to market. For pharma and biotech leaders navigating supply, compliance and growth, this conversation offers a clear look at where sterile manufacturing is headed — and how to prepare. Listen to the full interview.
The editorial staff had no role in this post's creation.